Literature DB >> 12576458

Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers.

Claire F Verschraegen1, Wei Hu, Yu Du, John Mendoza, Janet Early, Michael Deavers, Ralph S Freedman, Robert C Bast, Andrzej P Kudelka, John J Kavanagh, Beppino C Giovanella.   

Abstract

PURPOSE: The purpose of this study was to characterize cell cultures and xenografts derived from patients with ovarian cancer. EXPERIMENTAL
DESIGN: Ninety specimens from 67 patients were plated in RPMI 1640 or inoculated in nude mice. Growth characteristics of cell cultures and xenografts were determined. Expression of receptors for estrogen, progesterone, androgen, epithelial growth factor, fibroblast growth factor, HER-2/erbB-2/c-neu proto-oncogene, and the P53 expression were characterized by immunocytochemistry in 28 cell cultures.
RESULTS: Forty-nine percent of samples were cultured successfully in vitro. Ascitic and pleural effusion specimens were more likely to produce a cell culture or a xenograft than solid tissue specimens (P < 0.005). All of the cell cultures had an epithelial morphology, and 89% were aneuploid with a mean DNA index of 1.6 (range, 0.9-3.0). Of 54 and 61 specimens inoculated into nude mice i.p. and s.c., 15 (28%) and 18 (30%) produced a xenograft, respectively, with two-thirds of these xenografts being reproducibly tumorigenic. The median time to first passage was 21 weeks for cell cultures and 8-12 weeks for xenografts. Expression of epithelial growth factor receptor, HER-2/erbB-2/c-neu proto-oncogene, fibroblast growth factor receptor, estrogen, progesterone, and androgen was seen in 24, 21, 31, 17, 43, and 18%, respectively. P53 was overexpressed in 62% of cell cultures analyzed.
CONCLUSIONS: Ovarian cancer cells collected from effusions are easier to grow in vitro than in vivo. The only characteristic that may be associated with tumorigenicity was abnormal P53 expression. This panel of ovarian cancer materials provides useful models for biological or therapeutical studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12576458

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  18 in total

1.  Multiple initial culture conditions enhance the establishment of cell lines from primary ovarian cancer specimens.

Authors:  Cara C Bertozzi; Cheng-Yi Chang; Sonya Jairaj; Xiaochuan Shan; Jia Huang; Barbara L Weber; Christina S Chu; Richard G Carroll
Journal:  In Vitro Cell Dev Biol Anim       Date:  2006 Mar-Apr       Impact factor: 2.416

Review 2.  Patient-derived xenograft models in gynecologic malignancies.

Authors:  Clare L Scott; Helen J Mackay; Paul Haluska
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

3.  An orthotopic model of platinum-sensitive high grade serous fallopian tube carcinoma.

Authors:  Dineo Khabele; Oluwole Fadare; Annie Y Liu; Andrew J Wilson; Erika Wass; Kevin Osteen; Marta A Crispens
Journal:  Int J Clin Exp Pathol       Date:  2011-01-01

Review 4.  Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review.

Authors:  Ketao Jin; Lisong Teng; Yanping Shen; Kuifeng He; Zhenzhen Xu; Guangliang Li
Journal:  Clin Transl Oncol       Date:  2010-07       Impact factor: 3.405

5.  Determination of 35 cell surface antigen levels in malignant pleural effusions identifies CD24 as a marker of disseminated tumor cells.

Authors:  Xiaosai Yao; Myriam Labelle; Carla R Lamb; John M Dugan; Christina A Williamson; Donna R Spencer; Kimberly R Christ; Ryan O Keating; W David Lee; Glenn A Paradis; Shahinoor Begum; Richard O Hynes; K Dane Wittrup
Journal:  Int J Cancer       Date:  2013-07-13       Impact factor: 7.396

6.  Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours.

Authors:  Tan A Ince; Aurea D Sousa; Michelle A Jones; J Chuck Harrell; Elin S Agoston; Marit Krohn; Laura M Selfors; Wenbin Liu; Ken Chen; Mao Yong; Peter Buchwald; Bin Wang; Katherine S Hale; Evan Cohick; Petra Sergent; Abigail Witt; Zhanna Kozhekbaeva; Sizhen Gao; Agoston T Agoston; Melissa A Merritt; Rosemary Foster; Bo R Rueda; Christopher P Crum; Joan S Brugge; Gordon B Mills
Journal:  Nat Commun       Date:  2015-06-17       Impact factor: 14.919

7.  Establishment of a new representative model of human ovarian cancer in mice.

Authors:  Jianjun Zhang; Xinlian Chen; Gang Shi; Xiaoyan Xie; Hongqian Liu; Xuemei Zhang; Yi Lai; Yan Zuo; Zhong Chen; Shanling Liu; He Wang
Journal:  J Ovarian Res       Date:  2013-02-06       Impact factor: 4.234

Review 8.  Estrogen, progesterone and epithelial ovarian cancer.

Authors:  Shuk-Mei Ho
Journal:  Reprod Biol Endocrinol       Date:  2003-10-07       Impact factor: 5.211

Review 9.  Emerging and Evolving Ovarian Cancer Animal Models.

Authors:  Alexander S Bobbs; Jennifer M Cole; Karen D Cowden Dahl
Journal:  Cancer Growth Metastasis       Date:  2015-08-12

Review 10.  Current status and evolution of preclinical drug development models of epithelial ovarian cancer.

Authors:  Panagiotis A Konstantinopoulos; Ursula A Matulonis
Journal:  Front Oncol       Date:  2013-12-11       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.